One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Oxytocin Market

[ 英語タイトル ] Oxytocin Market- Growth, Trends, and Forecast (2020 – 2025)

Product Code : MDHC0089350
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 110
Category : Healthcare and Pharmaceuticals
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Bimeda
- GlaxoSmithKline PLC
- Grindeks
- JHP Pharmaceuticals
- Novartis AG
- Pfizer Inc.
- Shanghai Hefeng

[Report Description]

The oxytocin market studied is anticipated to register a CAGR of nearly 5.4%, during the forecast period.

· Certain factors that are driving the market growth include an increasing prevalence of pregnancy complications, a rising number of births globally, and growing awareness of induced labor and breastfeeding.

· Rising disposable incomes, especially in developing countries, and increasing awareness regarding pregnancy care products among women, increase in literacy rate of women, and increase in well-developed distribution channels for oxytocin products are the major factors driving the growth of the oxytocin market.

However, stringent regulations and high cost of oxytocin drug are expected to be the key restraints for the growth of the pregnancy products market.

Key Market Trends

Antepartum Holds Significant Share in the Oxytocin Market

Antepartum oxytocin injection (synthetic) is indicated for the initiation or improvement of uterine contractions, where it is desirable and considered suitable to achieve early vaginal delivery for fetal or maternal reasons. In the antepartum period, exogenous oxytocin is FDA-approved for strengthening uterine contractions with the aim of successful vaginal delivery of the fetus.

North America Dominates the Oxytocin Market

North American dominates the oxytocin products market, due to high awareness regarding pregnancy products and increasing expenditure on personal care products. However, Asia-Pacific is anticipated to grow tremendously during the forecast period, owing to factors, such as a rise in disposable incomes in developing economies, such as China and India, a rise in well-established distribution channels, and increasing awareness regarding oxytocin products through strong marketing activities by key players.

Competitive Landscape

The oxytocin market is competitive and consists of a few major players. Companies, like Bimeda, GlaxoSmithKline PLC, Grindeks, JHP Pharmaceuticals, KAPL, Novartis AG, Pfizer Inc., and Shanghai Hefeng, hold the substantial share in the market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Pregnancy Complications
4.2.2 Rising Number of Births Globally
4.2.3 Growing Awareness of Induced Labor and Breastfeeding
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 High Cost of Oxytocin Drug
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Indication
5.1.1 Antepartum
5.1.2 Postpartum
5.2 By Distribution Channel
5.2.1 Hospital Pharmacies
5.2.2 Drug Stores
5.2.3 Online Pharmacies
5.3 By Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.3.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Bimeda
6.1.2 GlaxoSmithKline PLC
6.1.3 Grindeks
6.1.4 JHP Pharmaceuticals
6.1.5 KAPL
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Shanghai Hefeng




Recommended reports